Latest On Eisai Co., Ltd (ESALF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-15 17:45 EST | News | Eisai GAAP EPS of ¥193.31, revenue of ¥744.4B | N/A |  |
| 2023-05-15 17:45 EST | News | Eisai Co., Ltd. (ESALF) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-05-14 12:27 EST | News | Biogen’s new Alzheimer’s drug to raise annual Medicare costs by up to $5B – study | N/A | |
| 2023-04-27 00:22 EST | News | Biogen gains as Medicare to cover new Alzheimer’s drug with full FDA approval | N/A | |
| 2023-04-21 15:08 EST | News | Eli Lilly expects Medicare coverage for Alzheimer's drugs - Reuters | N/A | |
| 2023-04-20 16:06 EST | News | Eisai: Potentially The Best Bet On The Alzheimer's Treatment Market | N/A | |
| 2023-04-17 15:31 EST | News | Biogen's Leqembi has questionable efficacy, cost effectiveness, ICER says | N/A | |
| 2023-04-10 15:28 EST | News | Biogen, Eisai to face FDA AdCom in June for full approval of Alzheimer's drug | N/A | |
| 2023-04-07 12:48 EST | News | Merck, Eisai end two Keytruda combination trials after missing main goals | N/A | |
| 2023-03-20 22:14 EST | News | Biogen, Eisai Alzheimer's drug Leqembi covered by VA | N/A | |
| 2023-03-10 16:44 EST | News | Eisai expects $7B sales from Biogen-partnered Alzheimer’s therapy in 2030 | N/A | |
| 2023-03-01 19:29 EST | News | Biogen, Eisai's Alzheimer's therapy lecanemab gets priority review in China | N/A | |
| 2023-02-28 12:58 EST | News | Biogen, Eisai's Alzheimer's therapy lecanemab gets priority review in Chinna | N/A | |
| 2023-02-26 04:27 EST | News | Eisai: Growth In Japan Markets, Leqembi The Main Long-Term Growth Driver | N/A | |
| 2023-02-23 08:51 EST | News | Medicare says coverage limits on Alzheimer’s drugs is not under review | N/A | |
| 2023-02-17 23:58 EST | News | Eisai exec expects full approval of Alzheimer's therapy Leqembi this summer - CNBC | N/A | |
| 2023-02-17 23:58 EST | News | Senators urge swift action to expand Medicare coverage for Alzheimer’s therapies | N/A | |
| 2023-02-06 11:50 EST | News | Eisai Co., Ltd. 2022 Q3 - Results - Earnings Call Presentation | N/A | |
| 2023-02-06 11:49 EST | News | Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Call Transcript | N/A | |
| 2023-01-30 08:23 EST | News | Biogen, Eisai's Alzheimer's drug lecanemab gets priority review in Japan | N/A | |
| 2023-01-27 15:55 EST | News | Biogen, Eisai's Alzheimer's drug lecanemab gets review in EU | N/A | |
| 2023-01-16 04:13 EST | News | Eisai files application in Japan for Alzheimer's drug lecanemab | N/A | |
| 2023-01-11 04:52 EST | News | Eisai files for approval of Alzheimer's drug lecanemab in EU | N/A | |
| 2023-01-07 21:12 EST | News | Biogen, Eisai's lecanemab gets Alzheimer's nod, but how successful it will be is uncertain | N/A | |
| 2023-01-06 19:18 EST | News | Biogen, Eisai's Alzheimer's treatment lecanemab approved by the FDA | N/A | |
| 2022-12-30 02:06 EST | News | Biogen, FDA faulted in congressional inquiry into Alzheimer’s drug approval | N/A | |
| 2022-12-23 17:17 EST | News | Eisai starts filing seeking approval for Alzheimer's drug lecanemab in China | N/A | |
| 2022-12-23 17:17 EST | News | Biogen/ Eisai deserve $30K price tag for new Alzheimer’s drug – Wells Fargo | N/A | |
| 2022-12-23 17:17 EST | News | Biogen, Eisai Alzheimer's candidate lecanemab linked to third patient death | N/A | |
| 2022-12-23 00:43 EST | News | Biogen, Lilly potential Alzheimer's drugs given lukewarm review by drug evaluation group | N/A | |
| 2022-12-22 06:48 EST | News | Astellas Pharma, Eisai, Daiichi Sankyo and Takeda join hands to reduce environmental burden in the field of pharmaceutical packaging | N/A | |
| 2022-12-08 17:45 EST | News | Biogen, Eisai prompt Medicare to reevaluate Alzheimer’s coverage after new data | N/A | |
| 2022-12-01 21:30 EST | News | Lecanemab And Alzheimer's: More Data | N/A | |
| 2022-12-01 21:30 EST | News | Lilly posts Phase 3 data to compare its Alzheimer’s drug vs. Biogen’s | N/A | |
| 2022-12-01 03:15 EST | News | Biogen rallies Alzheimer’s drug developers after full data for lecanemab | N/A | |
| 2022-11-30 09:40 EST | News | Biogen's lecanemab shows less cognitive decline with Alzheimer's, but more brain swelling | N/A | |
| 2022-11-30 09:39 EST | News | Biogen stock may see pressure after not mentioned in Alzheimer's presentation - analyst | N/A | |
| 2022-11-28 21:53 EST | News | Biogen drops after report on second death linked to Alzheimer’s candidate | N/A | |
| 2022-11-08 04:06 EST | News | Eisai Co., Ltd. (ESALF) Q2 2023 Earnings Call Transcript | N/A | |
| 2022-10-28 08:53 EST | News | Biogen slips amid reports of death linked to new Alzheimer’s drug | N/A | |
| 2022-10-01 02:41 EST | News | Eisai, Biogen And Alzheimer's: Never Say Die, Lecanemab To The Rescue | N/A | |
| 2022-08-23 20:43 EST | News | Eisai, C2N team up to build real-world evidence for blood-based tests for cognitive disorders | N/A | |
| 2022-08-06 18:11 EST | News | Eisai Co., Ltd. 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2022-08-06 18:11 EST | News | Eisai Co., Ltd. (ESALY) Management on Q1 2023 Results - Earnings Call Transcript | N/A | |
| 2022-07-20 01:05 EST | News | Eisai refocuses R&D efforts as cancer research unit shutters | N/A | |
| 2022-07-06 14:42 EST | News | Biogen, Eisai's Alzheimer's therapy lecanemab gets FDA priority review | N/A | |
| 2022-06-24 17:44 EST | News | Biogen pulls plug on Aduhelm real-world study on coverage woes | N/A | |
| 2022-05-14 06:50 EST | News | Eisai Co., Ltd. (ESALF) CEO Haruo Naito on Q4 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-10 18:31 EST | News | Biogen, Eisai finish filing with FDA for Alzheimer’s therapy lecanemab, seek priority review | N/A | |
| 2022-04-10 06:44 EST | News | How might the CMS decision on Biogen's Aduhelm impact other Alzheimer's candidates? | N/A | |
About Eisai Co., Ltd (ESALF):
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.
General
- Name Eisai Co., Ltd
- Symbol ESALF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 10,998
- Fiscal Year EndMarch
- Web URLhttp://www.eisai.co.jp
Valuation
- Trailing PE 34.36
- Forward PE 27.7
- Price/Sales (Trailing 12 Mt.) 3.16
- Price/Book (Most Recent Quarter) 3.33
- Enterprise Value Revenue 0.03
- Enterprise Value EBITDA 0.13
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $1.77
- Next Year EPS Estimate $2.57
- Profit Margin 13%
- Return on Assets 6%
- Return on Equity 14%
- Earnings Per Share $2.08
- Revenue Per Share $0
- Gross Profit 519.93 billion
- Quarterly Earnings Growth -3%
ESG Rating
Highlights
- Market Capitalization 20.03 billion
- PEG Ratio 244930
- Analyst Target Price $91.82
- Book Value Per Share $19.95
Share Statistics
- Shares Outstanding 286.58 million
- Shares Float 285.78 million
- % Held by Insiders 917%
- % Held by Institutions 37.94%
Technicals
- Beta 0.48
- 52 Week High $90.35
- 52 Week Low $22
- 50 Day Moving Average 72.3
- 200 Day Moving Average 76.63
Dividends
- Forward Annual Dividend Rate $1.49
- Forward Annual Dividend Yield 2.09%
- Payout Ratio 105%
- Dividend Date 2018-05-24
- ExDividend Date 2021-03-30
- Dividend Per Share $1.36
- Dividend Yield 0%
Eisai Co., Ltd (ESALF) Dividend Calendar:
ESALF's last dividend payment was made to shareholders on May 24, 2018.
Eisai Co., Ltd pays out 105% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Eisai Co., Ltd (ESALF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $N/A | $0.65 | ||
| 2020-09-30 | 2020-12-31 | $N/A | $0.65 | ||
| 2020-06-30 | 2020-09-30 | $N/A | $0.05 | $42.20 | -99.89% |
| 2020-03-31 | 2020-06-30 | $N/A | $0.79 | ||
| 2019-12-31 | 2020-03-31 | $1.72 billion | $1.57 | ||
| 2019-09-30 | 2019-12-31 | $1.34 billion | $1.49 | $63.85 | -97.67% |
| 2019-06-30 | 2019-09-30 | $1.42 billion | $0.17 | ||
| 2019-03-31 | 2019-06-30 | $1.58 billion | $0.70 | ||
| 2018-12-31 | 2019-03-31 | $1.43 billion | $0.74 | ||
| 2018-09-30 | 2018-12-31 | $1.38 billion | $0.23 | ||
| 2018-06-30 | 2018-09-30 | $1.38 billion | $0.62 | $36.30 | -98.28% |
| 2018-03-31 | 2018-06-30 | $1.51 billion | $0.39 | $96.80 | -99.6% |
| 2017-12-31 | 2018-03-31 | $1.37 billion | $0.78 | $36.70 | -97.88% |
| 2017-09-30 | 2017-12-31 | $1.27 billion | $0.29 | $24.20 | -98.81% |
| 2017-06-30 | 2017-09-30 | $1.26 billion | $0.28 | $24.90 | -98.88% |
| 2017-03-31 | 2017-06-30 | $129.87 billion | $0.30 | ||
| 2016-12-31 | 2017-03-31 | $0.03 | $30.50 | -99.9% | |
| 2016-09-30 | 2016-12-31 | $0.31 | $12.90 | -97.57% | |
| 2016-06-30 | 2016-09-30 | $0.28 | $32.65 | -99.14% | |
| 2016-03-31 | 2016-06-30 | $0.67 | $8.40 | -92.01% | |
| 2015-12-31 | 2016-03-31 | $0.52 | $21.80 | -97.63% | |
| 2015-09-30 | 2015-12-31 | $0.79 | |||
| 2015-06-30 | 2015-09-30 | $0.16 | $9.50 | -98.29% | |
| 2015-03-31 | 2015-06-30 | $0.16 | |||
| 2014-12-31 | 2015-03-31 | $0.19 | $24.00 | -99.21% | |
| 2014-09-30 | 2014-12-31 | $0.77 | $28.50 | -97.31% | |
| 2014-06-30 | 2014-09-30 | $0.15 | $20.30 | -99.26% | |
| 2014-03-31 | 2014-06-30 | $0.20 | $54.70 | -99.64% | |
| 2013-12-31 | 2014-03-31 | $0.12 | $50.30 | -99.77% | |
| 2013-09-30 | 2013-12-31 | $0.06 | |||
| 2013-06-30 | 2013-09-30 | $0.65 | |||
| 2013-03-31 | 2013-06-30 | $0.33 | |||
| 2012-12-31 | 2013-03-31 | $0.53 | |||
| 2012-09-30 | 2012-12-31 | $0.39 | |||
| 2012-06-30 | 2012-09-30 | $0.57 | |||
| 2012-03-31 | 2012-06-30 | $0.52 | |||
| 2011-12-31 | 2012-03-31 | $0.40 | |||
| 2011-09-30 | 2011-12-31 | $0.72 | |||
| 2011-06-30 | 2011-09-30 | $0.90 | |||
| 2011-03-31 | 2011-06-30 | $0.59 | |||
| 2010-12-31 | 2011-03-31 | $0.00 | |||
| 2010-09-30 | 2010-12-31 | $1.19 | |||
| 2010-06-30 | 2010-06-30 | $0.72 |
Eisai Co., Ltd (ESALF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 318.3 million |
| Income Before Tax | N/A | N/A | N/A | N/A | 387.19 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 603.53 million |
| Gross Profit | N/A | N/A | N/A | N/A | 1.32 billion |
| Ebit | N/A | N/A | N/A | N/A | 410.83 million |
| Operating Income | N/A | N/A | N/A | N/A | 410.83 million |
| Income Tax Expense | 4.2 billion | 613 million | 7.7 billion | 3.67 billion | -41.1 million |
| Total Revenue | N/A | N/A | N/A | N/A | 1.72 billion |
| Cost of Revenue | N/A | N/A | N/A | N/A | 400.85 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -23.63 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | 428.29 million |
| Net Income Applicable to Common Shares | 19.37 billion | 1.37 billion | 24.43 billion | 48.52 billion | 425.85 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | 33.53 million | 5.33 million |
| Change to Liabilities | N/A | N/A | 335 million | N/A | N/A |
| Total Cash Flow from Investing Activities | -4.92 billion | -12.5 billion | -1.17 billion | -26.4 million | -31.93 million |
| Net Borrowings | -2.86 billion | -2.37 billion | -26.19 billion | -38.34 million | -134.16 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | -249.13 million | -150.64 million |
| Change to Operating Activities | -2.24 billion | -22.89 billion | 46.74 billion | -233.73 million | 342339.01 |
| Change in Cash | N/A | N/A | N/A | -26.37 million | -93.44 million |
| Total Cash from Operating Activities | 8.6 billion | 10.05 billion | 73.57 billion | 191.25 million | 115.79 million |
| Depreciation | N/A | N/A | N/A | 79.46 million | 76.17 million |
| Other Cash Flow from Investing Activities | 12 million | 65 million | 88 million | 2.49 million | 3 million |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | -89 million | 215 million | 276179.52 | -16.48 million |
| Change to Net Income | 488 million | -172 million | 6.95 billion | -80.32 million | -23.5 million |
| Capital Expenditures | N/A | N/A | N/A | 23.94 million | 23.76 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 3.52 billion |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 5.93 billion |
| Other Current Liabilities | 121.24 billion | 125.33 billion | N/A | N/A | 1.44 billion |
| Total Assets | N/A | N/A | N/A | N/A | 9.68 billion |
| Common Stock | 44.99 billion | 44.99 billion | 44.99 billion | 44.99 billion | 414.14 million |
| Other Current Assets | 20.26 billion | 17.6 billion | N/A | N/A | 203.03 million |
| Retained Earnings | 505.64 billion | 509.58 billion | 507.96 billion | 505.36 billion | 4.25 billion |
| Other Liabilities | 50.04 billion | 50.69 billion | 50.51 billion | 52.6 billion | 476.19 million |
| Other Assets | 79.54 billion | 82.17 billion | 81.98 billion | 81.54 billion | 706.67 million |
| Cash | N/A | N/A | N/A | N/A | 1.96 billion |
| Total Current Liabilities | 191.43 billion | 203.23 billion | N/A | N/A | 2.54 billion |
| Other Stockholder Equity | 78.11 billion | 80.18 billion | 82.36 billion | 84.51 billion | 871.8 million |
| Property, Plant & Equipment | 143.48 billion | 143.1 billion | 144.31 billion | 144.64 billion | 1.28 billion |
| Total Current Assets | 495.62 billion | 504.52 billion | N/A | N/A | 4.6 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 438.39 million |
| Net Tangible Assets | 404.06 billion | 404.31 billion | 408.19 billion | 403.35 billion | 3.28 billion |
| Short Term Investments | N/A | N/A | N/A | N/A | 22.58 million |
| Long Term Debt | N/A | N/A | N/A | N/A | 505.78 million |
| Inventory | 78.95 billion | 74.93 billion | N/A | N/A | 611.57 million |
| Accounts Payable | 70.19 billion | 77.9 billion | N/A | N/A | 554.92 million |
Eisai Co., Ltd (ESALF) Chart:
Eisai Co., Ltd (ESALF) News:
Below you will find a list of latest news for Eisai Co., Ltd (ESALF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Eisai Co., Ltd (ESALF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Eisai Co., Ltd (ESALF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|